title: [Prevention of stress-induced damage of the upper gastrointestinal mucosa in patients during early postoperative period].
abstract: Stress-damage of upper gastro-intestinal tract (GIT) mucous membrane and gastro-intestinal hemorrhage (GIH) increase the lethality of patients in the departments of reanimation and intensive care unit. The purpose of this study is to evaluate effectiveness and safety of pantoprazole use in patients with at least one risk factor of upper GIT mucosa stresses-damage and GIH. An important part of this study was examination of 24-hour intragastric pH - control results in patients during 1-st day after the surgery.
  
  
  METHODS
  Pantoprazole antisecretory therapy conducted in 40 patients, 38 of which had at least one risk factor of upper GIT mucosa stresses-damage and GIH. If there are risk factors, in the postoperative period prescribed pantoprazole (controlok) 80 mg/day bolus intravenously, then went to 40 mg/day per os. The criteria of the preventive therapy efficiency were absence of manifest and/or clinically significant GIH symptoms, the need for emergency upper endoscopy and emergency surgery, caused by the GIH. Among the patients with risk factors were marked out 15 patients: liver cirrhosis, portal hypertension syndrome (esophagus and stomach varix), liver failure (Child-Pugh A/B), high risk of hemorrhage. Within 24 hours, a constant intragastric-Ph monitoring ws carried out.
  
  
  RESULTS
  During observation in all patients, which were undergoing upper GIT mucosa stress-damage prevention, there was no need for emergency upper endoscopy. No patients needed to carry out emergency surgery, caused by the GIH. Lethality rate in this group was absent.
  
  
  CONCLUSIONS
  The use of pantoprazole demonstrates its good efficiency and tolerance.
authors: V V
authors: VV
authors: Nikoda
authors: A V
authors: AV
authors: Bondarenko
authors: D N
authors: DN
authors: Kiriushin
authors: E D
authors: ED
authors: Liubivyĭ
authors: V I
authors: VI
authors: Stamov
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005745:Gastric Acidity Determination; D005753:Gastric Mucosa / Q000187:drug effects* / Q000378:metabolism; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D000077402:Pantoprazole; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control*; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D012307:Risk Factors; D013315:Stress, Psychological / Q000150:complications / Q000378:metabolism
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D054328:Proton Pump Inhibitors; D000077402:Pantoprazole